文献速递青光眼

曲波腺苷(trabodenoson)——一种A1受体选择性腺苷类似物——通过增加小鼠传统流出易度降低眼压

Trabodenoson, an Adenosine Mimetic With A1 Receptor Selectivity Lowers Intraocular Pressure by Increasing Conventional Outflow Facility in Mice.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

研究评估曲波腺苷降眼压作用与小梁网结构和功能变化的关系。年轻和老年小鼠局部使用曲波腺苷后眼压显著降低,治疗2天后流出易度较对照增加26%(老年小鼠)和30%(总体),3D人小梁网构建体中MMP-2活性及MMP-14丰度增加,纤维连接蛋白和胶原IV表达降低。

要点

  • 曲波腺苷局部给药后每天测试眼压均显著降低,持续至7天。
  • 治疗2天后流出易度较对照增加26%(老年小鼠)和30%(总体,P<0.05)。
  • 3D人小梁网构建体中曲波腺苷增加MMP-2活性和MMP-14丰度,降低纤维连接蛋白和胶原IV表达。

核心结论

  • 曲波腺苷改变小梁网细胞的细胞外基质周转并增加传统流出易度,这解释了其在年轻和老年小鼠中降低眼压的能力。

研究设计与样本

  • 六个独立的年轻和老年小鼠队列接受三种不同的每日一次局部曲波腺苷制剂,并与安慰剂滴眼液眼对比。
  • 使用回弹式眼压计在每日给药前测量眼压,在离体眼中测量流出易度,用示踪珠和标准组织学监测传统流出组织的流型和形态。
  • 平行培养三维人小梁网组织构建体(3D-HTM),用于测试曲波腺苷对胶原IV、纤维连接蛋白、基质金属蛋白酶(MMP)-2和MMP-14表达及MMP-2活性的影响。

主要发现

  • 局部给予曲波腺苷后每天测试眼压均显著降低,持续至7天。
  • 治疗2天后流出易度较溶媒对照增加26%(老年小鼠)和30%(总体,年轻加老年小鼠),差异有统计学意义(P<0.05)。
  • 治疗7天后流出易度较对照高15%(P=0.07)。
  • 治疗未影响大体形态,但示踪珠分布强度至第7天增加(P=0.05)。
  • 3D-HTM实验中曲波腺苷显著增加MMP-2活性和MMP-14丰度,同时降低纤维连接蛋白和胶原IV表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the relationship between the IOP-lowering effect of trabodenoson and the associated structural and functional changes in the trabecular meshwork (TM). METHODS: Six independent cohorts of young and aged mice were exposed to three different topical once-a-day formulations of trabodenoson and eyes were compared to those treated with placebo drops. IOP was measured daily just before drug administration using rebound tonometry. Outflow facility was measured in enucleated eyes. Flow patterns and morphology of conventional outflow tissues were monitored using tracer beads and standard histology, respectively. In parallel, three-dimensional human TM tissue constructs (3D-HTM) were grown and used in experiments to test effect of trabodenoson on the expression of collagen IV, fibronectin, matrix metalloproteinase (MMP)-2 and MMP-14 plus MMP-2 activity. RESULTS: Topical administration of trabodenoson significantly lowered IOP on every day tested, up to 7 days. After 2 days of treatment, outflow facility increased by 26% in aged mice and 30% overall (young and aged mice), which was significantly different from vehicle (P < 0.05). Outflow facility was 15% higher than controls after 7 days of treatment (P = 0.07). While gross morphology was not affected by treatment, the intensity of tracer bead distribution increased by day 7 (P = 0.05). Parallel experiments in 3D-HTM showed that trabodenoson treatment significantly increased MMP-2 activity and MMP-14 abundance, while decreasing fibronectin and collagen IV expression. CONCLUSIONS: Trabodenoson alters ECM turnover by TM cells and increases conventional outflow facility, which accounts for its ability to lower IOP in young and aged mice.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Li G, Torrejon KY, Unser AM, et al. Trabodenoson, an Adenosine Mimetic With A1 Receptor Selectivity Lowers Intraocular Pressure by Increasing Conventional Outflow Facility in Mice. Invest Ophthalmol Vis Sci. 2018. PMID: 29346804. doi:10.1167/iovs.17-23212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。